



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Anti-deltaEGFR [DH8.3] Bulk Size Ab00822-10.3-BT

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors. Developed in partnership with Ximbio ([www.ximbio.com](http://www.ximbio.com)).

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.

**Isotype and Format:** Human IgG1, Fc Silent™, Kappa

**Clone Number:** DH8.3

**Alternative Name(s) of Target:** ΔEGFR; Epidermal growth factor receptor; EC:2.7.10.1; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; EGFR; ERBB; ERBB1; HER1

**UniProt Accession Number of Target Protein:** P00533

**Published Application(s):** IP, WB, ELISA, FC, IHC

**Published Species Reactivity:** Human

**Immunogen:** This antibody was raised by immunising BALB/c mice with a synthetic peptide, known as 79E (LEEKKGNYVVTDHC), corresponding to the junctional sequence of the Δ2-7 EGFR deletion mutation.

**Specificity:** This antibody is specific for ΔEGFR (EGFR type III), a truncated form of the epidermal growth factor receptor that is commonly associated with cancer cells, especially glioblastoma cells. ΔEGFR lacks exons 2-7 of the external domain. This antibody does not cross-react with full-length EGFR.

**Application Notes:** This antibody has been used in fluorescence-activated cell sorting, Western blot and immunohistochemical analysis, using acetone-fixed frozen sections, of a tumour panel (Jungbluth et al, 2003). It does not stain normal tissues, which express wild-type EGFR (Jungbluth et al, 2003), and preferentially stains tumours expressing mutant receptors (Hills et al, 1995). This antibody has also been used in immunoprecipitation experiments (Hills et al, 1995) and ELISA analysis (Johns et al, 2002). This antibody has been shown to induce rapid internalisation of truncated EGFR by target cells (Johns et al, 2002), which could have therapeutic applications, given the tumour-restricted expression of ΔEGFR and its role in tumorigenesis.

**Antibody First Published in:** Hills et al. Specific targeting of a mutant, activated FGF receptor found in glioblastoma using a monoclonal antibody. *Int J Cancer*. 1995 Nov 15;63(4):537-43. [PMID:7591264](https://pubmed.ncbi.nlm.nih.gov/7591264/)

**Note on publication:** Describes the original generation of this antibody, and characterisation of its specificity in IP and WB experiments.

## Product Form

**Size:** 1 mg Purified antibody in bulk size.

**Purification:** Protein A affinity purified

**Supplied In:** PBS only.

**Storage Recommendation:** Store at 4°C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommended this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20°C.

**Concentration:** 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.